Iehle C, Radvanyi F, Gil Diez de Medina S, et al. 1999. Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol, 68:189-95. Imperato-McGinley J, Gautier T, Zirinsky K, et al. 1992. Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deﬁciency. J Clin Endocrinol Metab, 75:1022-6. Imperato-McGinley J, Guerrero L, Gautier T, et al. 1974. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science, 186:1213-15. Iversen P, Tyrrell CJ, Kaisary AV, et al. 2000. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol, 164: 1579-82. Jemal A, Siegel R, Ward E, et al. 2006. Cancer statistics, 2006. CA Cancer J Clin, 56:106-30. McConnell JD, Bruskewitz R, Walsh P, et al. 1998. The effect of ﬁnasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efﬁcacy and Safety Study Group. N Engl J Med, 338: 557-63. McConnell JD, Roehrborn CG, Bautista OM, et al. 2003. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med, 349:2387-98. McLeod DG, See WA, Klimberg I, et al. 2006. The bicalutamide 150 mg early prostate cancer program: ﬁndings of the North American trial at 7.7-year median followup. J Urol, 176:75-80. Oh WK, Manola J, Bittmann L, et al. 2003. Finasteride and ﬂutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology, 62:99-104. Partin AW, Rodriguez R. 2002. The molecular biology, endocrinology, and physiology of the prostate and seminal vesicles. In: Walsh PC, Retik A, Vaughan E, et al. (eds). Campbell’s Urology. 8th ed. Philadelphia: Saunders, pp 1237-96. Potosky AL, Knopf K, Clegg LX, et al. 2001. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol, 19:3750-7. Presti JC Jr, Fair WR, Andriole G, et al. 1992. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of ﬁnasteride (MK-906) on stage D prostate cancer. J Urol, 148:1201-4. Ries L, Harkins D, Krapcho M, et al. 2006. SEER Cancer Statistics Review, 1975-2003. National Cancer Institute [online]. Accessed 2 October 2006. URL: http://seer.cancer.gov/csr/1975_2003/. Rittmaster RS, Stoner E, Thompson DL, et al. 1989. Effect of MK-906, a speciﬁc 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men. J Androl, 10:259-62. Roehrborn CG, Boyle P, Nickel JC, et al. 2002. Efﬁcacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology, 60:434-41. Scardino PT. 2003. The prevention of prostate cancer—the dilemma continues. N Engl J Med, 349:297-9. 5 alpha-reductase inhibitors in prostate cancer Scholz MC, Jennrich RI, Strum SB, et al. 2006. Intermittent use of testosterone inactivating pharmaceuticals using ﬁnasteride prolongs the time off period. J Urol, 175:1673-8. Spry NA, Kristjanson L, Hooton B, et al. 2006. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer, 42:1083-92. Steiner JF. 1996. Clinical pharmacokinetics and pharmacodynamics of ﬁnasteride. Clin Pharmacokinetics, 30:16-27. Stoner E. 1990. The clinical development of a 5-alpha-reductase inhibitor, ﬁnasteride. J Steroid Biochem Mol Biol, 37:375-8. Stoner E. 1992. The clinical effects of a 5 alpha-reductase inhibitor, ﬁnasteride, on benign prostatic hyperplasia. The Finasteride Study Group. J Urol, 147:1298-302. Tay MH, Kaufman DS, Regan MM, et al. 2004. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. Ann Oncol, 15:974-8. Thompson IM, Ankerst DP, Chi C, et al. 2005. Operating characteristics of prostate-speciﬁc antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA, 294:66-70. Thompson IM, Chi C, Ankerst DP, et al. 2006. Effect of ﬁnasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst, 98:1128-33. Thompson IM, Goodman PJ, Tangen CM, et al. 2003. The inﬂuence of ﬁnasteride on the development of prostate cancer. N Engl J Med, 349:215-24. Tooher R, Swindle P, Woo H, et al. 2006. Laparoscopic radical prostatectomy for localized prostate cancer: a systematic review of comparative studies. J Urol, 175:2011-17. Tsukamoto S, Akaza H, Onozawa M, et al. 1998. A ﬁve-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer, 82:531-7. Tyrrell CJ, Kaisary AV, Iversen P, et al. 1998. A randomised comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol, 33:447-56. Walsh PC, Madden JD, Harrod MJ, et al. 1974. Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med, 291:944-9. Wang LG, Mencher SK, McCarron JP, et al. 2004. The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review. Oncol Rep, 11:1325-9. Wenderoth UK, George FW, Wilson JD. 1983. The effect of a 5 alpha- reductase inhibitor on androgen-mediated growth of the dog prostate. Endocrinology, 113:569-73. Zaccheo T, Giudici D, di Salle E. 1997. Effect of turosteride, a 5 alpha- reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma. Prostate, 30:85-91. Zaccheo T, Giudici D, di Salle E. 1998. Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats. Prostate, 35:237-42. Clinical Interventions in Aging 2006:1(4) 431